摘要
Dear Editor,Cytidine analogs,such as decitabine(DAC)and cytarabine(ara-C),have been widely used in the clinical treatment for several cancer types,including myelodysplastic syndrome and acute myeloid leukemia(AML;Appelbaum et al.1999;Saba 2007).However,drug resistance causing treatment failure and disease relapse is an unresolved problem to date.Certain cancer cells rely on the salvage enzymes cytidine deaminase(CDA)and dCMP deaminase(DCTD)to inactivate these cytidine derivative drugs by deamination(Jamieson et al.1987;Ebrahem et al.2012).It is imperative to develop new categories of chemotherapeutic nucleosides to overcome the drug resistance caused by such increased cellular deamination activity.
基金
supported by the National Natural Science Foundation of China(Nos.32000894,32000420)
the Ministry of Science and Technology of China(No.2018YFA0800302)
the China postdoctoral Science Foundation(No.2019M651357)
the Shanghai Sailing Program(No.18YF1412200)
the Chinese Academy of Sciences Interdisciplinary Innovation Team(No.JCTD-2018-14)
the Natural Science Foundation of Shanghai(NO.20ZR1408000)
Fudan University Start-up Research Grant(Nos.IDH1340038,IDH1340045,IDH1340046,IDH1340059)
the Chinese Academy of Medical Sciences(CAMS)Innovation Fund for Medical Sciences(CIFMS,No.2019-I2M-5-077).
